Hong Shen and Carl G. Maki Pages 560 - 568 ( 9 )
Restoring p53 activity by inhibiting the interaction between p53 and MDM2 represents an attractive approach for cancer therapy. To this end, a number of small-molecule p53-MDM2 binding inhibitors have been developed during the past several years. Nutlin-3 is a potent and selective small-molecule MDM2 antagonist that has shown considerable promise in pre-clinical studies. This review will highlight recent advances in the development of small-molecule MDM2 antagonists as potential cancer therapeutics, with special emphasis on Nutlin-3.
Nutlin-3,p53,MDM2,therapy,antagonist,apoptosis,MDMX,p14/ARF,NUTLIN,doxorubicin,therapeutic,choriocarcinoma,Molecular Mechanisms,Antitumor,Perifosine
, Department of Anatomy and Cell Biology Rush University Medical Center 1750 W Harrison Ave Jelke Building, room 1306.